213 related articles for article (PubMed ID: 32084576)
1. Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease.
Bhattamisra SK; Shak AT; Xi LW; Safian NH; Choudhury H; Lim WM; Shahzad N; Alhakamy NA; Anwer MK; Radhakrishnan AK; Md S
Int J Pharm; 2020 Apr; 579():119148. PubMed ID: 32084576
[TBL] [Abstract][Full Text] [Related]
2. Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects.
Yan X; Xu L; Bi C; Duan D; Chu L; Yu X; Wu Z; Wang A; Sun K
Int J Nanomedicine; 2018; 13():273-281. PubMed ID: 29391788
[TBL] [Abstract][Full Text] [Related]
3. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment.
Bi C; Wang A; Chu Y; Liu S; Mu H; Liu W; Wu Z; Sun K; Li Y
Int J Nanomedicine; 2016; 11():6547-6559. PubMed ID: 27994458
[TBL] [Abstract][Full Text] [Related]
4. Facile nose-to-brain delivery of rotigotine-loaded polymer micelles thermosensitive hydrogels: In vitro characterization and in vivo behavior study.
Wang F; Yang Z; Liu M; Tao Y; Li Z; Wu Z; Gui S
Int J Pharm; 2020 Mar; 577():119046. PubMed ID: 31982559
[TBL] [Abstract][Full Text] [Related]
5. Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Curr Drug Discov Technol; 2019; 16(4):417-425. PubMed ID: 29669501
[TBL] [Abstract][Full Text] [Related]
6. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity.
Raj R; Wairkar S; Sridhar V; Gaud R
Int J Biol Macromol; 2018 Apr; 109():27-35. PubMed ID: 29247729
[TBL] [Abstract][Full Text] [Related]
7. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model.
Md S; Khan RA; Mustafa G; Chuttani K; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2013 Feb; 48(3):393-405. PubMed ID: 23266466
[TBL] [Abstract][Full Text] [Related]
8. Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats.
Wang A; Wang L; Sun K; Liu W; Sha C; Li Y
Pharm Res; 2012 Sep; 29(9):2367-76. PubMed ID: 22549738
[TBL] [Abstract][Full Text] [Related]
9. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
[TBL] [Abstract][Full Text] [Related]
10. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
Boroojerdi B; Wolff HM; Braun M; Scheller DK
Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
[TBL] [Abstract][Full Text] [Related]
11. Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.
Eskow Jaunarajs KL; Standaert DG; Viegas TX; Bentley MD; Fang Z; Dizman B; Yoon K; Weimer R; Ravenscroft P; Johnston TH; Hill MP; Brotchie JM; Moreadith RW
Mov Disord; 2013 Oct; 28(12):1675-82. PubMed ID: 24014074
[TBL] [Abstract][Full Text] [Related]
12. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
Zareba G
Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
[TBL] [Abstract][Full Text] [Related]
13. Effects of rotigotine and rotigotine extended-release microsphere therapy on myocardial ischemic injury in mice.
Lv H; Yu F; Sha C; Huang Y; Lu Y; Zhang L; Zhai R; Wang T; Fu F
Eur J Pharm Sci; 2019 Jun; 134():1-6. PubMed ID: 30959104
[TBL] [Abstract][Full Text] [Related]
14. Fabrication, Optimization, and Evaluation of Rotigotine-Loaded Chitosan Nanoparticles for Nose-To-Brain Delivery.
Tzeyung AS; Md S; Bhattamisra SK; Madheswaran T; Alhakamy NA; Aldawsari HM; Radhakrishnan AK
Pharmaceutics; 2019 Jan; 11(1):. PubMed ID: 30634665
[TBL] [Abstract][Full Text] [Related]
15. The development of the rotigotine transdermal patch: a historical perspective.
Waters C
Neurol Clin; 2013 Aug; 31(3 Suppl):S37-50. PubMed ID: 23931953
[TBL] [Abstract][Full Text] [Related]
16. Self-Assembled Lecithin-Chitosan Nanoparticles Improved Rotigotine Nose-to-Brain Delivery and Brain Targeting Efficiency.
Saha P; Singh P; Kathuria H; Chitkara D; Pandey MM
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986712
[TBL] [Abstract][Full Text] [Related]
17. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting.
Jafarieh O; Md S; Ali M; Baboota S; Sahni JK; Kumari B; Bhatnagar A; Ali J
Drug Dev Ind Pharm; 2015; 41(10):1674-81. PubMed ID: 25496439
[TBL] [Abstract][Full Text] [Related]
18. Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats.
Pahuja R; Seth K; Shukla A; Shukla RK; Bhatnagar P; Chauhan LK; Saxena PN; Arun J; Chaudhari BP; Patel DK; Singh SP; Shukla R; Khanna VK; Kumar P; Chaturvedi RK; Gupta KC
ACS Nano; 2015 May; 9(5):4850-71. PubMed ID: 25825926
[TBL] [Abstract][Full Text] [Related]
19. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
[TBL] [Abstract][Full Text] [Related]
20. Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method.
Md S; Haque S; Fazil M; Kumar M; Baboota S; Sahni JK; Ali J
Expert Opin Drug Deliv; 2014 Jun; 11(6):827-42. PubMed ID: 24655115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
